Cargando…

Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment

Remdesivir was approved by the U.S.A. Food and Drug administration for emergency use to interfere with the replication of SARS CoV-2 virus (the agent that causes COVID-19) in adults and children hospitalized with severe disease. The crystal structure of the metabolite of remdesivir (Monophosphate of...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Lindsey S, Gund, Tamara M, Narayan, Mahesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662030/
https://www.ncbi.nlm.nih.gov/pubmed/33185784
http://dx.doi.org/10.1007/s10930-020-09942-9

Ejemplares similares